Company Filing History:
5 out of 5 
1 out of 4 
1 out of 1 Years Active: 2006-2009
Title: Innovations in Newborn Genetic Screening by Donald H. Chace
Introduction
Donald H. Chace is a prominent inventor based in Upper St. Clair, PA (US). He has made significant contributions to the field of genetic screening, particularly for newborns. With a total of 7 patents to his name, Chace has developed methods that enhance the accuracy and efficiency of clinical testing.
Latest Patents
Chace's latest patents include a clinical method for the genetic screening of newborns using tandem mass spectrometry. This innovative method utilizes electrospray tandem mass spectrometry to improve existing protocols. It ensures accurate and consistent results at the clinical level through enhanced quality controls and quality assurance protocols. The method involves the use of specific additives in precise concentrations of internal standards, allowing for the detailed control of twenty metabolites. These metabolites are scanned and compared to known spectra results. The process includes quality assurance steps that assess whether samples are contaminated, drug-ridden, diagnosable, or unacceptable. All results are organized in spreadsheet form and exported to a database for daily output results and trend analysis. This method provides high-throughput and quality results, ensuring efficient and accurate genetic testing for newborns.
Career Highlights
Throughout his career, Donald H. Chace has worked with notable companies such as Pediatrix Screening, Inc. and Sigma-Tau Pharmaceuticals, Inc. His work has significantly impacted the field of newborn screening, leading to advancements in clinical practices.
Collaborations
Chace has collaborated with professionals in his field, including GianFranco Fornasini, to further enhance the methodologies used in genetic screening.
Conclusion
Donald H. Chace's contributions to the field of genetic screening for newborns have established him as a key innovator. His patented methods improve the accuracy and efficiency of clinical testing, ultimately benefiting newborn health.